EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Rhea-AI Summary
EDAP (Nasdaq: EDAP) will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Wednesday, March 18, 2026. CEO Ryan Rhodes will deliver a virtual presentation and, with CFO Ken Mobeck, host one-on-one investor meetings from 12:00–12:30 PM ET. A live and archived webcast is available.
Positive
- None.
Negative
- None.
News Market Reaction – EDAP
In the Mar 10 session, EDAP gained 4.77%, reflecting a moderate positive market reaction. Argus tracked a trough of -14.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Earnings date notice | Neutral | +6.5% | Announced timing for Q4 and full-year 2025 financial results release. |
| Feb 12 | Board change | Neutral | -2.6% | Appointed David Horn to Board and announced Glen French’s departure. |
| Jan 12 | Prelim revenue, guidance | Positive | +11.4% | Reported preliminary record 2025 HIFU revenue and issued 2026 revenue guidance. |
| Nov 20 | Regulatory clearance | Positive | +5.8% | Received FDA 510(k) clearance for upgraded Focal One HIFU imaging and workflow. |
| Nov 18 | Conference appearance | Neutral | +3.4% | Announced presentation and 1x1 meetings at Piper Sandler healthcare conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific announcements, particularly on revenue and product milestones, have generally coincided with positive price reactions, while governance changes showed one divergence.
Over the last several months, EDAP has reported multiple operational and investor-relations milestones. Preliminary record HIFU revenue and 2026 guidance on Jan 12, 2026 and an FDA 510(k) clearance on Nov 20, 2025 both saw solid positive reactions. Prior conference participation on Dec 2, 2025 and a recent earnings-date announcement on Mar 25, 2026 also aligned with gains. A February 2026 board change was the only recent event followed by a negative move, highlighting generally constructive news sensitivity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18th, 2026
AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
Date: Wednesday, March 18th
Time: 12:00-12:30 PM ET
Format: Virtual Presentation and 1x1 investor meetings
Webcast:https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/6YGp8gAgsNuJhACXjn75JB
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Investor Contact
Investor Relations
EDAP TMS SA
Investor.Relations@focalone.com
